Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.

ABSTRACT:

Background and objective

Insulin degludec is a basal insulin with a slow and distinct absorption mechanism resulting in an ultra-long, flat, and stable pharmacokinetic profile in patients with diabetes mellitus. The aim of this study was to examine the effect of hepatic impairment on the single-dose pharmacokinetics of insulin degludec.

Methods

Twenty-four subjects, allocated to one of four groups (n=6 per group) based on level of hepatic impairment (normal hepatic function, Child-Pugh grade A, B, or C), were administered a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected to measure pharmacokinetic parameters.

Results

No difference was observed in pharmacokinetic parameters [area u

SUBMITTER: Kupcova V 

PROVIDER: S-EPMC3899454 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature